Table 2. Clinico-pathological characteristics of patients with metastatic prostate cancer with their respective CTC counts.
|
ISET
|
CellSearch | |||||||
|---|---|---|---|---|---|---|---|---|
| Patients | Age a | Histology | Gleason grade | TNM stage | PSA (μg l–1) b | CTC/7.5 ml | Atypical cells/7.5 ml | CTC/7.5 ml |
| P1 | 80 | IA | 8 | T2N0M1 | 196 | 12 | 5 | 8 |
| P2 | 61 | IA | 6 | T2N0M1 | 14.6 | 2 | 5 | 1 |
| P3 | 75 | IA | 7 | T3N0M1 | 1095 | 248 | 0 | 90 |
| P4 | 66 | IA | ND | T2N0M1 | 1394 | 30 | 120 | 643 |
| P5 | 73 | IA | 9 | T2N0M1 | 603 | 4 | 35 | 1 |
| P6 | 73 | IA | 9 | T2N0M1 | 60 | 12 | 55 | 2 |
| P7 | 82 | IA | 8 | T3N0M1 | 97 | 4 | 13 | 0 |
| P8 | 62 | IA | 7 | T3N0M1 | 2669 | 1 | 18 | 16 121 |
| P9 | 70 | IA | 8 | T2N1M1 | 68 | 25 | 16 | 11 |
| P10 | 78 | IA | 8 | T2N0M0 | 354 | 20 | 59 | 17 |
| P11 | 88 | IA | 8 | T3N0M1 | 77 | 30 | 30 | 18 |
| P12 | 50 | IA | 9 | T1N0M0 | 101 | 6 | 18 | 8 |
| P13 | 50 | IA | 9 | T3N0M1 | 93 | 35 | 18 | 5 |
| P14 | 67 | IA | 7 | T2N0M1 | 1.8 | 16 | 15 | 2 |
| P15 | 67 | IA | 9 | T3dN0M1 | 3.8 | 2 | 9 | 0 |
| P16 | 83 | IA | 7 | T2N0M1 | 689 | 14 | 43 | 278 |
| P17 | 78 | IA | 10 | T4N0M1 | 50 | 19 | 24 | 1 |
| P18 | 82 | IA | 9 | T2N0M1 | 85 | 25 | 43 | 95 |
| P19 | 68 | IA | 9 | T3N2M0 | 0.2 | 18 | 68 | 4 |
| P20 | 80 | IA | 8 | T3N1M0 | 40 | 50 | 185 | 36 |
Abbreviations: CTC=circulating tumour cell; IA=infiltrative adenocarcinoma; ND=not determined; PSA=prostate serum antigen; TNM=tumour node metastasis.
a
Age (years) at the moment of CTC analysis.
b
PSA at the moment of CTC analysis.